Coronavirus Drug Discovery
-10%
portes grátis
Coronavirus Drug Discovery
Volume 3: Druggable Targets and In Silico Update
Egbuna, Chukwuebuka
Elsevier - Health Sciences Division
07/2022
406
Mole
Inglês
9780323955782
15 a 20 dias
450
Descrição não disponível.
PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS 1. SARS-CoV-2 genome sequencing and promising druggable targets 2. Signaling pathways implicated in SARS-CoV2 infection 3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease 4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions
PART 2: COMPUTATIONAL APPROACHES 5. Application of computational tools for coronavirus drug discovery 6. In silico Approaches in Drug Discovery for SARS-CoV-2 7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies 8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals 12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry
PART 2: COMPUTATIONAL APPROACHES 5. Application of computational tools for coronavirus drug discovery 6. In silico Approaches in Drug Discovery for SARS-CoV-2 7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies 8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals 12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Structure based drug discovery; 2019-nCoV; 4-Aminoquinolines; ADME; ADMET; Antidiabetic compounds; Antiviral; Approved drugs; Bioactive compound; Bioactive compounds; Bioinformatics; Cellular entry; Chinese medicine; Computational chemistry; Coronavirus; Coronaviruses; COVID-19Cytokine injury; COVID-19Dietary polyphenols; COVID-19Disease; COVID-19Drug designing; COVID-19Homology modeling; COVID-19Insilico; COVID-19Medicinal plants; Covid-19MERS; Docking; Drug design; Drug discovery; Drug lipophilicity; Drug repurposing; Drug solubility; Druggable targets; Genome sequencing; Hepatitis; Herbal plants; In silico investigation; Infections; Inflammasome; JAK/STAT signaling; Lipid inhibitors; MAPK pathway; Measles; Medicinal chemistry; Medicinal plants; Molecular docking; Molecular dynamics simulations; Mutations; Natural drugs; Natural medicine; Natural products; NF-?B; Pandemic; Pathway-targeted drugs; Phylogeny; Physicochemical properties; Phytochemicals; Phytotherapy; Preclinical stages; Punicagranatum; QSAR; RAS; SAR-CoV-2 proteins; SARS; SARS-CoV-2SARS-CoV-2 main protease enzyme (Mpro; SARS-CoV-2 Mpro; SARS-CoV-2StarDrop; SARS-CoV-2Transmission; SARS-CoV-2Vaccine development; Skin eruptions; Skin exanthems; UPR stress; Vaccine; Viral exanthematous infection; Viral infection; Virtual screening; Virulence factors; Virus
PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS 1. SARS-CoV-2 genome sequencing and promising druggable targets 2. Signaling pathways implicated in SARS-CoV2 infection 3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease 4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions
PART 2: COMPUTATIONAL APPROACHES 5. Application of computational tools for coronavirus drug discovery 6. In silico Approaches in Drug Discovery for SARS-CoV-2 7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies 8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals 12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry
PART 2: COMPUTATIONAL APPROACHES 5. Application of computational tools for coronavirus drug discovery 6. In silico Approaches in Drug Discovery for SARS-CoV-2 7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies 8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals 12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Structure based drug discovery; 2019-nCoV; 4-Aminoquinolines; ADME; ADMET; Antidiabetic compounds; Antiviral; Approved drugs; Bioactive compound; Bioactive compounds; Bioinformatics; Cellular entry; Chinese medicine; Computational chemistry; Coronavirus; Coronaviruses; COVID-19Cytokine injury; COVID-19Dietary polyphenols; COVID-19Disease; COVID-19Drug designing; COVID-19Homology modeling; COVID-19Insilico; COVID-19Medicinal plants; Covid-19MERS; Docking; Drug design; Drug discovery; Drug lipophilicity; Drug repurposing; Drug solubility; Druggable targets; Genome sequencing; Hepatitis; Herbal plants; In silico investigation; Infections; Inflammasome; JAK/STAT signaling; Lipid inhibitors; MAPK pathway; Measles; Medicinal chemistry; Medicinal plants; Molecular docking; Molecular dynamics simulations; Mutations; Natural drugs; Natural medicine; Natural products; NF-?B; Pandemic; Pathway-targeted drugs; Phylogeny; Physicochemical properties; Phytochemicals; Phytotherapy; Preclinical stages; Punicagranatum; QSAR; RAS; SAR-CoV-2 proteins; SARS; SARS-CoV-2SARS-CoV-2 main protease enzyme (Mpro; SARS-CoV-2 Mpro; SARS-CoV-2StarDrop; SARS-CoV-2Transmission; SARS-CoV-2Vaccine development; Skin eruptions; Skin exanthems; UPR stress; Vaccine; Viral exanthematous infection; Viral infection; Virtual screening; Virulence factors; Virus
